Trial Profile
A One-Year, Randomized, Double-Blind, Placebo-Controlled Trial of Rosiglitazone in Non-Alcoholic Steatohepatitis
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 09 Nov 2015
Price :
$35
*
At a glance
- Drugs Rosiglitazone (Primary)
- Indications Non-alcoholic steatohepatitis
- Focus Adverse reactions; Therapeutic Use
- Acronyms FLIRT; LIDO-Trials01